Browsing by Author "Warren, Simon"

Now showing 1 - 6 of 6
  • Thumbnail Image
    Item
    Cutaneous collagenous vasculopathy: development after coronary artery bypass surgery
    (eScholarship Publishing, University of California, 2018) Rahnama-Moghadam, Sahand; Burgin, Callie; Gilbert, Juliana; Warren, Simon; Dermatology, School of Medicine
    Cutaneous collagenous vasculopathy (CCV) is a rare benign microangiopathy of the superficial dermal vessels. Clinically, it is characterized by widespread, asymptomatic development of cutaneous telangiectasia in the absence of systemic symptoms. Morphologically, it most resembles generalized essential telangiectasia and other telangiectatic syndromes such as telangiectasia macularis eruptiva perstans (TMEP), ataxia telangiectasia, and hereditary hemorrhagic telangiectasia. It is distinctive in its histology, showing characteristic dilated thick-walled blood vessels in the superficial dermis. The thickened walls of these superficial dermal blood vessels demonstrate reduplication of the basement membrane on PAS staining. We report a 63-year-old man with CCV with this condition for 20 years, starting in 1996. He was diagnosed in the past as having essential telangiectasia. The development of the telangectasias occurred after coronary artery bypass grafting, also performed in 1996. This case not only demonstrates the characteristic clinical and histologic findings, but also suggests a possible mechanism. Moreover, it illustrates that cases of generalized essential telangiectasia may in fact be CCV that are misclassified.
  • Thumbnail Image
    Item
    Gamma-delta mycosis fungoides in a posttransplant patient
    (Elsevier, 2020-03) Bitter, Julie M.; Warren, Simon; Mark, Lawrence A.; Medicine, School of Medicine
    Mycosis fungoides (MF) is a clonal T-cell lymphoproliferative disorder of the skin that accounts for an estimated 50% to 60% of cutaneous T cell lymphoma (CTCL) cases.1,2 The gamma-delta (gd) subtype of MF (GD-MF) is a rare variant, with only a few cases reported in the literature and only 1 in a patient after solid organ transplant.3 Here we present a case of GD-MF developing after liver transplantation in an older man.
  • Thumbnail Image
    Item
    Lichenoid Reaction Pattern with Pseudoepitheliomatous Hyperplasia - A Rare Tattoo Reaction: A Case Report and Review of the Literature
    (Karger, 2018-12-05) Broussard-Steinberg, Candace; Zemtsov, Alexander; Strausburg, Matthew; Zemtsov, Gregory; Warren, Simon; Dermatology, School of Medicine
    Pseudoepitheliomatous hyperplasia is a benign histologic reaction pattern that in rare cases can occur shortly after a tattooing procedure. We describe a case of pseudoepitheliomatous hyperplasia in two tattoos on the same patient 1 year after filling with the same batch of red ink.
  • Thumbnail Image
    Item
    Mice lacking epidermal PPARγ exhibit a marked augmentation in photocarcinogenesis associated with increased UVB-induced apoptosis, inflammation and barrier dysfunction
    (Wiley, 2012-10) Sahu, Ravi P.; DaSilva, Sonia C.; Rashid, Badri; Martel, Kellie Clay; Jernigan, Danielle; Mehta, Shama R.; Mohamed, Deena R.; Rezania, Samin; Bradish, Joshua R.; Armstrong, Andrew B.; Warren, Simon; Konger, Raymond L.; Department of Medicine, IU School of Medicine
    Recent studies suggest that peroxisome proliferator-activated receptor gamma (PPARγ) agonists may have cancer chemopreventive activity. Other studies have shown that loss of epidermal PPARγ results in enhanced chemical carcinogenesis in mice via unknown mechanisms. However, ultraviolet B (UVB) exposure represents the primary etiological agent for skin cancer formation and the role of PPARγ in photobiology and photocarcinogenesis is unknown. In previous studies, we demonstrated that UVB irradiation of cells results in the formation of oxidized glycerophosphocholines that exhibit PPARγ ligand activity. We therefore hypothesized that PPARγ would prove to be a chemopreventive target in photocarcinogenesis. We first showed that UVB irradiation of mouse skin causes generation of PPARγ agonist species in vivo. We then generated SKH-1 hairless, albino mice deficient in epidermal Pparg (Pparg-/-(epi)) using a cytokeratin 14 driven Cre-LoxP strategy. Using a chronic model of UVB photocarcinogenesis, we next showed that Pparg-/-(epi) mice exhibit an earlier onset of tumor formation, increased tumor burden and tumor progression. Increased tumor burden in Pparg-/-(epi) mice was accompanied by a significant increase in epidermal hyperplasia and p53 positive epidermal cells in surrounding skin lacking tumors. After acute UVB irradiation, Pparg-/-(epi) mice exhibited an augmentation of both UVB-induced Caspase 3/7 activity and inflammation. Increased apoptosis and inflammation was also observed after treatment with the PPARγ antagonist GW9662. With chronic UVB irradiation, Pparg-/-(epi) mice exhibited a sustained increase in erythema and transepidermal water loss relative to wildtype littermates. This suggests that PPARγ agonists could have possible chemopreventive activity in non-melanoma skin cancer.
  • Thumbnail Image
    Item
    Multifocal Rosai-Dorfman disease with involvement of the pinna
    (Elsevier, 2017-05) Hirt, Molly B.; Heskett, Jordan; Veerula, Vindhya; Warren, Simon; Avashia-Khemka, Nidhi; Mark, Lawrence A.; Department of Dermatology, School of Medicine
  • Thumbnail Image
    Item
    Primary cutaneous peripheral T-cell lymphoma, not otherwise specified with mammalian target of rapamycin mutation: A novel finding for targeted treatment
    (Elsevier, 2020-12) De la Sancha, Carlo; Burgin, Callie; Warren, Simon; Hoffmann, Kristin; Davé, Utpal; Nassiri, Mehdi; Pathology and Laboratory Medicine, School of Medicine
    Primary cutaneous peripheral T-cell lymphoma, not otherwise specified (pcPTCL-NOS) is a rare, progressive, and often fatal disease with no specific treatment regimen that presents as rapidly enlarging plaques or nodules. Here, we present a case of progressive pcPTCL-NOS with mammalian target of rapamycin (mTOR) mutation and variable T-cell antigen expression. mTOR mutation in pcPTCL-NOS may represent a new therapeutic target.